https://the483.com/kailera-625m-record-biotech-ipo/ The 483 en 2026-04-19T00:45:09.000Z Kailera Raises $625M in Record Biotech IPO on Nasdaq https://the483.com/federal-savings-bank-occ-va-deception/ The 483 en 2026-04-18T23:14:45.000Z OCC Hits Federal Savings Bank With Consent Order for Deceptive VA Loan Ads https://the483.com/fincen-whistleblower-award-nprm/ The 483 en 2026-04-18T22:12:22.000Z FinCEN Filed NPRM Offering 10-30% Cut to Financial Crime Whistleblowers https://the483.com/kraken-bitnomial-550m-cftc-derivatives/ The 483 en 2026-04-18T21:32:09.236Z Kraken Paid $550M for Bitnomial's Triple CFTC License Stack https://the483.com/revmed-pan-ras-phase3-aacr26/ The 483 en 2026-04-18T17:15:53.000Z RevMed Doubles Phase 3 Survival With Pan-RAS Drug at AACR25 https://the483.com/ucb-bought-neurona-650m/ The 483 en 2026-04-18T16:15:32.000Z UCB Bought Neurona for $650M, Up to $1.15B Total https://the483.com/jpmorgan-occ-250m-trade-order/ The 483 en 2026-04-18T15:17:35.000Z OCC Clears JPMorgan's $250M Trade Surveillance Order After 2 Years https://the483.com/fifth-third-comerica-500k-conversion/ The 483 en 2026-04-18T14:18:44.000Z Bought Comerica. Now Fifth Third Converts 500,000 Customers by Labor Day https://the483.com/merck-mk-2010-nsclc-phase3/ The 483 en 2026-04-18T13:45:11.304Z Merck Hits 55% NSCLC ORR With MK-2010, Won't Commit to Phase 3 https://the483.com/kailera-625m-ipo-biotech-record/ The 483 en 2026-04-18T00:40:31.000Z Raised $625M at $16 a Share, Kailera Tops Moderna's 2018 IPO Record https://the483.com/revolution-medicines-buyout-30b-cancer/ The 483 en 2026-04-17T23:17:57.000Z Topped $30B: Revolution Medicines Buyout Climbs on Cancer Win https://the483.com/teva-lilly-176m-patent-reinstated/ The 483 en 2026-04-17T22:17:10.000Z Revived: $176.5M Patent Verdict Leaves Lilly to Evaluate Options https://the483.com/kailera-625m-ipo-obesity/ The 483 en 2026-04-17T21:33:47.984Z Kailera Prices $625m IPO, One of the Largest Biotech Offerings Since Moderna 2018 https://the483.com/replimune-rp1-fda-rejected-twice/ The 483 en 2026-04-17T15:27:56.000Z Rejected Twice: Replimune's RP1 and the 22 Scientists Who Disagreed https://the483.com/kailera-625m-ipo-record-biotech/ The 483 en 2026-04-17T14:31:48.000Z Priced at $16, Kailera Raises $625M in Largest Biotech IPO Since 2018 https://the483.com/daiichi-sankyo-suntory-consumer-health-sale/ The 483 en 2026-04-17T13:51:42.788Z Daiichi Sankyo Sold $1.55B Consumer Unit to Suntory https://the483.com/zuk-liberty-bank-ai-bet/ The 483 en 2026-04-17T01:38:49.000Z Filed: Nir Zuk's Bid for $442M-Asset Liberty Bank